FIRST HALF TURNOVER REACHES € 95.7 MILLION, A 54% INCREASE
- Strong growth in traditional activities excluding COVID : + 31% at € 40.9 million
- Extension of the installed instrument park
- Continuation of the proprietary products development strategy
Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life sciences, today presents its consolidated half-year turnover as at
New semester of strong growth
- Continued sales linked to the diagnosis of COVID (€ 54.8 million, or 57% of turnover);
- Strong growth in traditional activities, excluding COVID (€ 40.9 million, or 43% of turnover).
in M€ | H1 2021 | H1 2020 | var. | |
COVID | 54,8 | 31,0 | +77% | |
Excluding COVID | 40,9 | 31,1 | +31% | |
Total | 95,7 | 62,2 | +54% | |
not audited |
Maintaining a high market share in COVID diagnostics
During the first half of the year, the Group continued to enrich its COVID diagnostic offering with PCR, antigen and self-tests. In line with its strategy focused on increasing its share of proprietary products, almost all of these new tests were developed in-house (EBX and EBS ranges). For example,
Compared to the second half of 2020, COVID revenue is down (€ 54.8m vs € 86m) under the cross effect of an anticipated drop in selling prices and a market switch in favor of pharmacy networks, in which the Group has limited marketing presence.
Thanks to its range of reagents and its penetration of large private and hospital laboratories,
Strong growth in revenues excluding COVID at + 31% (+ 23% organically)
The increased visibility of
The strong momentum initiated in the context of the health crisis, combined with the recurrence of sales inherent in
Significant financial resources to deploy the strategy
With gross cash currently exceeding € 80 million,
At the same time, the Group continues to selectively develop its distribution portfolio.
On the basis of the new dimension acquired in 2020,
Next financial meeting
Half-year results 2021:
Disclaimer This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, profitability or events to differ materially from those anticipated. In addition, Eurobio Scientific, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications. Such statistical data and predictions are used in this press release for information purposes only. Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. About Eurobio Scientific For more information, please visit : www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP |
Contacts |
Group Tel. +33(0) 1 69 79 64 80 | Calyptus Investors relations Tel. +33(1) 53 65 68 68 eurobio-scientific@calyptus.net |
Attachment
- PR_Eurobio Scientific_CA_S1_21_EN
© OMX, source